GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,219 | -227 | -20,884 | -15,300 | -8,419 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -1,729 |
| Other Working Capital | 1,054 | -15 | -1,894 | -5,158 | -1,761 |
| Other Operating Activity | -3,676 | -2,664 | 7,561 | 9,539 | 3,908 |
| Operating Cash Flow | $-4,841 | $-2,906 | $-15,217 | $-10,919 | $-8,001 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -4,332 | -6,989 | N/A | 4,639 | 4,614 |
| Purchase Of Investment | N/A | N/A | 12,145 | N/A | N/A |
| Investing Cash Flow | $-4,332 | $-6,989 | $12,145 | $4,639 | $4,614 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,268 | 6,268 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | -224 | -223 | -223 |
| Financing Cash Flow | $6,268 | $6,268 | $-224 | $-223 | $-223 |
| Beginning Cash Position | 5,672 | 5,672 | 8,968 | 8,968 | 8,968 |
| End Cash Position | 2,767 | 2,045 | 5,672 | 2,465 | 5,358 |
| Net Cash Flow | $-2,905 | $-3,627 | $-3,296 | $-6,503 | $-3,610 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,841 | -2,906 | -15,217 | -10,919 | -8,001 |
| Free Cash Flow | -4,841 | -2,906 | -15,217 | -10,919 | -8,001 |